Loading company…
Neushen Therapeutics develops gene and small-molecule treatments for central nervous system conditions.
Founded in 2021, Neushen Therapeutics develops central nervous system drug candidates using AAV gene therapy and small-molecule platforms. Its research includes candidates for conditions such as schizophrenia and Alzheimer's disease. The company is based in Shanghai, China. In September 2026, it raised over USD 80 million in Series B funding from B Capital, Legend Capital, MPCi, Hainan Zhenmai Private Equity Fund Management, Shanghai State-owned Capital Investment Leading Fund, Lilly Asia Ventures and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in